Shares of DKSH, the Swiss distribution and market-expansion services group, fell 5.55% to CHF63.00 on Tuesday, the lowest level since July 21, underperforming the broader Swiss SMI which declined about 0.3%. The drop followed a downgrade from Berenberg, which reduced its rating on DKSH from Buy to Hold and cut its price target to CHF68 from CHF75, implying roughly 8% upside from current levels.
Berenberg cited concerns over earnings and margin pressures, noting that its revised earnings-per-share expectations for 2026 are approximately 8% below consensus and roughly 9% below consensus for the 2026–2028 period. The broker also highlighted that meeting DKSH’s full-year guidance will require a strong performance in the second half of the year.
DKSH reiterated its full-year guidance alongside its first-half results, but Berenberg emphasized that the group’s ability to achieve these targets remains contingent on improving macroeconomic conditions and operational execution. The company’s shares had risen about 16% over the prior year before the downgrade.
The group’s performance is heavily tied to its healthcare and consumer goods segments, which together account for 83% of sales. Healthcare, which represents 74% of healthcare sales, operates on thin EBIT margins of 1%–2%, with upfront investments in new contracts expected to continue pressuring margins through 2027. The consumer goods segment saw its core EBIT margin decline to 2% in the first half, the lowest level since 2021, driven by higher promotional activity, weaker consumer spending, and a shift toward lower-priced products.
Geographically, DKSH remains heavily exposed to Asia-Pacific, which accounts for about 94% of sales, with Thailand contributing roughly 30% of total revenue. Berenberg noted that regional GDP growth is slowing and elevated inflation could further weigh on discretionary spending and corporate investment, adding to the group’s near-term challenges.
